Company: LGNZZ
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0000886163-25-000025
Chunk: 58

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 58
---
 Company and the NASDAQ Biotechnology Index. See additional disclosure in footnote (1) under the “Summary Compensation Table” above.

(6) Matthew Korenberg resigned on October 15, 2024. Mr. Korenberg’s bonus was paid out assuming a target bonus of 50% of base salary, with a corporate performance achievement of 50% of target for the duration of his tenure in 2024.

(7) Amounts disclosed in this row reflect the incremental fair value expense calculated in accordance with Topic 718 that was recognized in connection with the modification of the outstanding 2022 option awards, the vesting of which was accelerated in connection with Mr. Korenberg’s separation from the Company. This amount is included in the Option Awards column of the Summary Compensation Table.

(8) Amounts disclosed in this row reflect the incremental fair value expense calculated in accordance with Topic 718 that was recognized in connection with the modification of the outstanding 2023 option awards, the vesting of which was accelerated in connection with Mr. Korenberg’s separation from the Company. This amount is included in the Option Awards column of the Summary Compensation Table.

(9) Amounts disclosed in this row reflect the incremental fair value expense calculated in accordance with Topic 718 that was recognized in connection with the modification of the outstanding 2024 option awards, the vesting of which was accelerated in connection with Mr. Korenberg’s separation from the Company. This amount is included in the Option Awards column of the Summary Compensation Table.

(10) Amounts disclosed in this row reflect the incremental fair value expense calculated in accordance with Topic 718 that was recognized in connection with the modification of the outstanding 2022 PSUs, the vesting of which was accelerated in connection with Mr. Korenberg’s separation from the Company. This amount is included in the Stock Awards column of the Summary Compensation Table.

(11) Amounts disclosed in this row reflect the incremental fair value expense calculated in accordance with Topic 718 that was recognized in connection with the modification of the outstanding 2023 PSUs, the vesting of which was accelerated in connection with Mr. Korenberg’s separation from the Company. This amount is included in the Stock Awards column of the Summary Compensation Table.

(12) Amounts disclosed in this row reflect the incremental fair value expense calculated in accordance with Topic 718 that was recognized in connection with the modification of the outstanding 2024 PSUs, the vesting of which was accelerated in connection with Mr